2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)-
Turner Syndrome
National Institute of Neurological Disorders and Stroke (NINDS)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Turner Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Serostim Massachusetts General Hospital | Phase 3 | BB |
Medroxyprogesterone Eli Lilly and Company | Phase 3 | BB |
Orsythia Component Ethinyl Estradiol Eli Lilly and Company | Phase 3 | BB |
Tmtds Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 | B |
Same molecule, other indications
2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →